Skeletal muscle cells: From local inflammatory response to active immunity

Gene Therapy

Volumn 18, Issue 2, 2011, Pages 109-116

  Marino, M ^a   Scuderi, F ^a   Provenzano, C ^a   Bartoccioni, E ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

adhesion molecules; cytokines; DNA vaccination; gene delivery; Toll like receptors

Indexed keywords

ALPHA INTERFERON; APC; CELL ADHESION MOLECULE; CHEMOKINE; CXCL1 CHEMOKINE; CYTOKINE; DNA; DNA VACCINE; GAMMA INTERFERON; HLA G ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; CHINESE MEDICINE; CPG ISLAND; DNA IMMUNIZATION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPOTENT STEM CELL; MUSCLE CELL; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; REVIEW; SATELLITE CELL; SKELETAL MUSCLE; T LYMPHOCYTE;

AVIAN PROTEINS; CYTOKINES; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNITY, ACTIVE; IMMUNOMODULATION; INFLAMMATION; MUSCLE, SKELETAL; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; VACCINES, DNA;

EID: 79951518015     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.124     Document Type: Review

References (98)

1. Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005; 26: 373-380. (Pubitemid 40835843)
2. Bischoff R, Franzini-Armstrong C. Satellite and stem cells in muscle regeneration. In: Engel A and Franzini-Armstrong C (eds) Myology. McGraw-Hill: New York, 2004 pp 66-86.
3. Miyazaki S, Miyazaki JI. In vivo DNA electrotransfer into muscle. Develop Growth Differ 2008; 50: 1-5.
4. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 2005; 54: 3-20.
5. Wolff JA, Dowty ME, Jiao S, Repetto G, Berg RK, Ludtke JJ et al. Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle. J Cell Sci 1992; 103: 1249-1259. (Pubitemid 23042268)
6. Stieger K, Belbellaa B, Le Guiner C, Moullier P, Rolling F. In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev 2009; 61: 527-541.
7. Latta-Mahieu M, Rolland M, Caillet C, Wang M, Kennel P, Mahfouz I et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther 2002; 13: 1611-1620. (Pubitemid 35034681)
8. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 2008; 4: 449-452.
9. Goodsell A, Zhou F, Gupta S, Singh M, Malyala P, Kazzaz J et al. Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology 2008; 123: 378-389. (Pubitemid 351171190)
10. Liu MA. Gene-based vaccines: recent developments. Curr Opin Mol Ther 2010; 12: 86-93.
11. Selby M, Goldbeck C, Pertile T, Walsh R, Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000; 29: 147-152.
12. Gramzinski RA, Millan CL, Obaldia N, Hoffman SL, Davis HL. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med 1998; 4: 109-118. (Pubitemid 28223950)
13. Tollefsen S, Tjelle T, Schneider J, Harboe M, Wiker H, Hewinson G et al. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 2002; 10: 3370-3378. (Pubitemid 35256081)
14. Durieux AC, Bonnefoy R, Busso T, Freyssenet D. In vivo gene electrotransfer into skeletal muscle: effects of plasmid DNA on the occurrence and extent of muscle damage. J Gene Med 2004; 6: 809-816. (Pubitemid 40228097)
15. Grønevik E, Mathiesen I, Lømo T. Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J Gene Med 2005; 7: 1246-1254. (Pubitemid 41335176)
16. Frost RA, Lang CH. Regulation of muscle growth by pathogen-associated molecules. J Anim Sci 2008; 86 (Suppl): E84-E93.
17. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004; 4: 512-520. (Pubitemid 38931766)
18. Takeda K. Evolution and integration of innate immune recognition systems: the toll-like receptors. J Endotoxin Res 2005; 11: 51-55. (Pubitemid 40533080)
19. Hemmi H, Akira S. TLR signalling and the function of dendritic cells. Chem Immunol Allergy 2005; 86: 120-135. (Pubitemid 40905001)
20. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168: 554-561. (Pubitemid 34049553)
21. Gallucci S, Provenzano C, Mazzarelli P, Scuderi F, Bartoccioni E. Myoblasts produce IL-6 in response to inflammatory stimuli. Int Immunol 1998; 10: 267-273. (Pubitemid 28132712)
22. Frost RA, Nystrom GJ, Lang CH. Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: role of the Jun NH2-terminal kinase. Am J Physiol Regul Integr Comp Physiol 2003; 285: R1153-R1164. (Pubitemid 37296368)
23. Schreiner B, Voss J, Wischhusen J, Dombrowski Y, Steinle A, Lochmüller H et al. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB J 2006; 20: 118-120. (Pubitemid 43100486)
24. Frost RA, Nystrom GJ, Lang CH. Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes. Am J Physiol Regul Integr Comp Physiol 2006; 290: R773-R784.
25. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511. (Pubitemid 38931765)
26. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099-1103. (Pubitemid 32391041)
27. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738. (Pubitemid 33009951)
28. Boyd JH, Divangahi M, Yahiaoui L, Gvozdic D, Qureshi S, Petrof BJ. Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin. Infect Immun 2006; 74: 6829-6838. (Pubitemid 44913158)
29. Verthelyi D. Adjuvant properties of CpG oligonucleotides in primates. Methods Mol Med 2006; 127: 139-158.
30. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-760. (Pubitemid 34293438)
31. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161: 3042-3049. (Pubitemid 28425730)
32. Gurunathan S, Wu CY, Freidag BL, Seder RA. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 2000; 12: 442-447. (Pubitemid 30410351)
33. Chen YS, Hsiao YS, Lin HH, Liu Y, Chen YL. CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice. Infect Immun 2006; 74: 1699-1705. (Pubitemid 43346803)
34. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest 1996; 98: 1119-1129. (Pubitemid 26299924)
35. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immuno-genicity of DNA vaccines. J Immunol 1997; 158: 3635-3639. (Pubitemid 127488716)
36. Pedersen BK, Akerström TC, Nielsen AR, Fisher CP. Role of myokines in exercise and metabolism. J Appl Physiol 2007; 103: 1093-1098. (Pubitemid 47358897)
37. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008; 88: 1379-1406.
38. Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003; 28: 659-682. (Pubitemid 37484828)
39. Bartoccioni E, Michaelis D, Hohlfeld R. Constitutive and cytokine-induced production of interleukin-6 by human myoblasts. Immunol Lett 1994; 42: 135-138. (Pubitemid 24378122)
40. De Rossi M, Bernasconi P, Baggi F, De Waal Malefyt R, Mantegazza R. Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation. Int Immunol 2000; 12: 1329-1335. (Pubitemid 30657777)
41. Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S et al. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol 2002; 14: 917-924.
42. Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998; 113: 407-414. (Pubitemid 28410566)
43. Volpes R, Van den Oord JJ, Desmet VJ. Immunohistochemical study of adhesion molecules in liver inflammation. Hepatology 1990; 12: 59-65. (Pubitemid 20234008)
44. Bartoccioni E, Gallucci S, Scuderi F, Ricci E, Servidei S, Broccolini A et al. MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin Exp Immunol 1994; 95: 166-172. (Pubitemid 24207121)
45. Tews DS, Goebel HH. Expression of cell adhesion molecules in inflammatory myopathies. J Neuroimmunol 1995; 59: 185-194.
46. Malorni W, Iosi F, Zarcone D, Grossi CE, Arancia G. Role of adhesion molecules in the mechanism of non-MHC major histocompatibility complex) restricted cell-mediated cytotoxicity. Scanning Microsc 1993; 7: 323-331.
47. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 1991; 147: 3788-3793.
48. Marino M, Scuderi F, Mazzarelli P, Mannella F, Provenzano C, Bartoccioni E. Constitutive and cytokine-induced expression of MHC and intercellular adhesion molecule-1 (ICAM-1) on human myoblasts. J Neuroimmunol 2001; 116: 94-101. (Pubitemid 32322643)
49. Figarella-Branger D, Schleinitz N, Boutière-Albanèse B, Camoin L, Bardin N, Guis S et al. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies. J Rheumatol 2006; 33: 1623-1630. (Pubitemid 44168836)
50. Meyer DM, Dustin ML, Carron CP. Characterization of intercellular adhesion molecule-1 ectodomain (sICAM-1) as an inhibitor of lymphocyte function-associated molecule-1 interaction with ICAM-1. J Immunol 1995; 155: 3578-3584.
51. Marino M, Scuderi F, Mannella F, Bartoccioni E. TGF-beta 1 and IL-10 modulate IL-1 beta-induced membrane and soluble ICAM-1 in human myoblasts. J Neuroimmunol 2003; 134: 151-157. (Pubitemid 36050840)
52. Remick DG. Interleukin-8. Crit Care Med 2005; 33: S466-S467. (Pubitemid 41785990)
53. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003; 24: 25-29. (Pubitemid 35462110)
54. Bartoccioni E, Scuderi F, Marino M, Provenzano C. IL-6, monocyte infiltration and parenchymal cells. Trends Immunol 2003; 24: 299-300.
55. Marino M, Scuderi F, Provenzano C, Scheller J, Rose-John S, Bartoccioni E. IL-6 regulates MCP-1, ICAM-1 and IL-6 expression in human myoblasts. J Neuroimmunol 2008; 196: 41-48.
56. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007; 110: 1748-1755. (Pubitemid 47443884)
57. Scuderi F, Mannella F, Marino M, Provenzano C, Bartoccioni E. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol 2006; 176: 9-15. (Pubitemid 44080332)
58. Sugiura T, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. J Immunol 2000; 164: 6593-6600. (Pubitemid 30408846)
59. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14: 705-714. (Pubitemid 32592418)
60. Jostock T, Müllberg J, Ö zbek S, Atreya R, Blinn G, Voltz N et al. Soluble gp130 is the natural inhibitor of soluble IL-6R transsignaling responses. Eur J Biochem 2003; 268: 160-167. (Pubitemid 32052260)
61. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008; 111: 1021-1028. (Pubitemid 351213379)
62. Nowell MA, Williams AS, Carty SA, Scheller J, Hayes AJ, Jones GW et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 2009; 182: 613-622.
63. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric castleman disease. Blood 2005; 106: 2627-2632. (Pubitemid 41510733)
64. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21: 491-501. (Pubitemid 39370505)
65. Mazzarelli P, Scuderi F, Mistretta G, Provenzano C, Bartoccioni E. Effect of transforming growth factor-beta1 on interleukin-6 secretion in human myoblasts. J Neuroimmu-nol 1998; 87: 185-188. (Pubitemid 28319860)
66. + T cells. Int J Mol Med 2004; 14: 571-576.
67. Umemura M, Nishimura H, Saito K, Yajima T, Matsuzaki G, Mizuno S et al. Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus calmette-guérin vaccination. Infect Immun 2003; 71: 6045-6048. (Pubitemid 37205658)
68. Li W, Li S, Hu Y, Tang B, Cui L, He W. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting. Vaccine 2008; 26: 3282-3290.
69. Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 2007; 25: 4967-4982. (Pubitemid 46843429)
70. Cui YL, He SY, Xue MF, Zhang J, Wang HX, Yao Y. Protective effect of a multiantigenic DNA vaccine against Toxoplasma gondii with co-delivery of IL-12 in mice. Parasite Immunol 2008; 30: 309-313. (Pubitemid 351514548)
71. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146. (Pubitemid 37328691)
72. Dustin ML, Tseng SY, Varma R, Campi G. T cell-dendritic cell immunological synapses. Curr Opin Immunol 2006; 18: 512-516. (Pubitemid 43947585)
73. Englund P, Lindroos E, Nennesmo I, Klareskog L, Lundberg IE. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am J Pathol 2001; 159: 1263-1273. (Pubitemid 32947956)
74. Curnow SJ, Willcox N, Vincent A. Induction of primary immune responses by allogeneic human myoblasts: dissection of the cell types required for proliferation, IFNgamma secretion and cytotoxicity. J Neuroimmunol 1998; 86: 53-62. (Pubitemid 28293949)
75. Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myoblasts as antigen-presenting cells. J Immunol 1992; 149: 661-667.
76. Curnow J, Corlett L, Willcox N, Vincent A. Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response. J Neuroimmunol 2001; 115: 127-134. (Pubitemid 32245660)
77. Behrens L, Kerschensteiner M, Misgeld T, Goebels N, Wekerle H, Hohlfeld R. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 1998; 161: 5943-5951. (Pubitemid 28535962)
78. Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999; 155: 453-460. (Pubitemid 29370395)
79. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548. (Pubitemid 40563179)
80. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2: 116-126. (Pubitemid 37323235)
81. Wiendl H, Mitsdoerffer M, Schneider D, Melms A, Lochmuller H, Hohlfeld R et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003; 126: 1026-1035. (Pubitemid 36522946)
82. + T cell cytotoxicity. Brain 2004; 127: 1182-1190. (Pubitemid 38623051)
83. Wiendl H, Mitsdoerffer M, Schneider D, Chen L, Lochmüller H, Melms A et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J 2003; 17: 1892-1894.
84. Waschbisch A, Wintterle S, Lochmüller H, Walter MC, Wischhusen J, Kieseier BC et al. Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. Arthritis Rheum 2008; 58: 3600-3608.
85. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002; 20: 29-53. (Pubitemid 34293419)
86. Fries KM, Sempowski GD, Gaspari AA, Blieden T, Looney RJ, Phipps RP. CD40 expression by human fibroblasts. Clin Immunol Immunopathol 1995; 77: 42-51.
87. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Sci USA 1995; 92: 4342-4346.
88. Yang Y, Haecker SE, Su Q, Wilson JM. Immunology of gene therapy with adenoviral vector in mouse skeletal muscle. Hum Mol Genet 1996; 5: 1703-1712. (Pubitemid 26372405)
89. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984; 38: 287-292. (Pubitemid 14035181)
90. + T cells. J Exp Med 1995; 181: 1863-1868.
91. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325: 1487-1498.
92. Hohlfeld R, Engel AG. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991; 29: 498-507.
93. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8: 108-120. (Pubitemid 351161331)
94. Wiendl H, Behrens L, Maier S, Johnson MA, Weiss EH, Hohlfeld R. Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Ann Neurol 2000; 48: 679-684.
95. Rouas-Freiss N, Gonçalves RM, Menier C, Dausset J, Carosella ED, Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA, 1997, 94, 11520-11525.
96. Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol 2001; 22: 553-555. (Pubitemid 33016401)
97. Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED, HLA-G2, -G3 and -G4 isoforms expressed as nonmature cell-surface glycoproteins inhibit NK and antigenspecific CTLcytolysis. J Immunol. 2001, 166, 5018-5026. (Pubitemid 32280714)
98. Wiendl H, Mitsdoerffer M, Weller M. Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies. Hum Immunol 2003; 64: 1050-1056. (Pubitemid 37413714)